Day: May 21, 2023

This article or press release has no online content. Please download the associated documents for more information.Attachment2022-Half-year-financial-report

8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5/8) complete response (MRD 10-5) was demonstrated by NXC-201 with zero ICANs, zero grade 4 CRS 62% (5/8) had NYHA classification III or IV heart failure prior to treatment with NXC-201 Best responder duration of response was 16.5 months with response ongoing as of the data cutoff date of May 11, 2023LOS ANGELES, May 21, 2023 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), today announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 (NCT04720313) study of its novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 for the treatment of patients with relapsed or refractory multiple myeloma...

Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo Dupixent is the first and only investigational biologic for COPD that has significantly improved lung function at 12 and 52 weeks, with numerical improvements seen as early as 2 weeks Dupixent significantly improved quality of life, with numerical improvements as early as 4 weeks after initiating treatment, and respiratory symptoms COPD is the third leading cause of death worldwide, with no new treatment approaches approved in more than a decade; trial enrolled patients with moderate-to-severe disease and evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells/µL) TARRYTOWN, N.Y. and PARIS, May 21, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals,...

Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of MedicineDupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo Dupixent is the first and only investigational biologic for COPD that has significantly improved lung function at 12 and 52 weeks, with numerical improvements seen as early as 2 weeks Dupixent significantly improved quality of life, with numerical improvements as early as 4 weeks after initiating treatment, and respiratory symptoms COPD is the third leading cause of death worldwide, with no new treatment approaches approved in more than a decade; trial enrolled patients with moderate-to-severe disease and evidence of...

As announced after the Annual General Meeting of Iceland Seafood on March 16th the company’s board of directors was given an authorization to increase the company’s share capital by up to ISK 150.000.000 nominal value. The board of directors has now decided to utilize this authorization in full, to strengthen the company’s financial position. The share increase is done in accordance with paragraph 3 of Article 4 of the company’s Articles of Association. In total 150.000.000 new shares will be issued, Investors have subscribed for all the shares at a price of 6.00 per share, which is equal to the highest bid on Nasdaq Iceland at end of Friday May 19th. The new shares will be paid for in cash, they will be issued electronically and registered at Nasdaq CDN and the registration at the Company Registry of the Iceland Revenue and Customs. Total...

Eleven-university strong network to grow the next-generation workforce and advance semiconductor-based research in both countries HIROSHIMA, Japan, May 20, 2023 (GLOBE NEWSWIRE) — Micron Technology, Inc., the largest foreign investor in Japan over the last five years, today announced the launch of the U.S.-Japan University Partnership for Workforce Advancement and Research & Development in Semiconductors (UPWARDS) for the Future. Aimed at cultivating a more robust and highly-skilled semiconductor workforce for the two countries, the partnership will drive emerging research while increasing the pipeline of students studying a semiconductor curriculum. U.S. Secretary of State Antony J. Blinken and Japanese Minister of Education, Culture, Sports, Science and Technology Keiko Nagaoka presided over the signing of a memorandum of...